CellGen AI
An AI-driven biotech using machine learning to design and optimize next-generation cell therapies for immunology and oncology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $35M
AI Company Overview
An AI-driven biotech using machine learning to design and optimize next-generation cell therapies for immunology and oncology.
ImmunologyOncology
Technology Platform
A proprietary AI and machine learning platform that analyzes immunological data to predict and design optimized cell therapy constructs.
Funding History
1Total raised:$35M
Series A$35M
Opportunities
Potential to significantly reduce the time and cost of developing complex cell therapies by using predictive AI models.
Risk Factors
High risk of technical validation, as AI predictions may not reliably translate to effective clinical therapies.
Competitive Landscape
Competes with other AI-driven drug discovery platforms, but its niche focus on cell therapy design differentiates it in a crowded field.